四川双马(000935) - 2025 Q2 - 季度财报

Important Notice, Table of Contents, and Definitions Important Notice The board and senior management guarantee report accuracy, advise on investment risks, and confirm no cash dividends or bonus shares for the period - The company's board of directors and senior management commit to the truthfulness, accuracy, and completeness of the report content, advising investors to pay attention to the risks and countermeasures in Section III 'Management Discussion and Analysis'[4] - The company plans not to distribute cash dividends, bonus shares, or convert capital reserves into share capital during the reporting period[5] Table of Contents This section lists the detailed table of contents, including company profile, management discussion and analysis, corporate governance, significant matters, share changes, bond information, financial reports, and other submitted data - The report's main sections include company profile and key financial indicators, management discussion and analysis, corporate governance, environment and society, significant matters, share changes and shareholder information, bond-related information, financial report, and a catalog of reference documents[7][8] Definitions This section provides definitions for common terms used in the report, covering company and subsidiary names, financial and investment terms, and biological and pharmaceutical professional terms to ensure clear understanding - The report defines abbreviations for the company and its subsidiaries, such as "Sichuan Shuangma", "Shuangma Yibin", and "Shenzhen Jianyuan"[10] - It explains professional terms in finance and investment, such as IPO (Initial Public Offering), VC (Venture Capital), and PE (Private Equity)[10] - Key concepts in the biopharmaceutical field are detailed, including ADC (Antibody-Drug Conjugate), peptides, GLP-1 (Glucagon-Like Peptide-1), CDMO (Contract Development and Manufacturing Organization), DMF filing (Drug Master File), and GMP/cGMP (Good Manufacturing Practice/current Good Manufacturing Practice)[10][12] Company Profile and Key Financial Indicators Company Profile Sichuan Harmony Shuangma Co, Ltd, stock ticker "Sichuan Shuangma" and stock code 000935, is listed on the Shenzhen Stock Exchange, with Xie Jianping as its legal representative - The company's stock abbreviation is "Sichuan Shuangma", stock code 000935, listed on the Shenzhen Stock Exchange[15] - The company's legal representative is Xie Jianping[15] Contact Person and Information The company's Board Secretary is Huang Canwen, Securities Affairs Representative is Jing Jing, with contact address in Chengdu, Sichuan, and provided phone, fax, and email - The Board Secretary is Huang Canwen, and the Securities Affairs Representative is Jing Jing[16] - The company's contact address is 26th Floor, Office Building 1, Chengdu International Finance Square, No 1, Section 3, Hongxing Road, Jinjiang District, Chengdu, Sichuan Province[16] - The investor inquiry hotline is 028-63231548, and the email address is public.sm@sc-shuangma.com[16] Other Information During the reporting period, there were no changes to the company's registered address, office address, website, email, or information disclosure and archiving locations, with specific details available in the 2024 annual report - The company's contact information, information disclosure, and archiving locations remained unchanged during the reporting period, with specific details available in the 2024 annual report[17][18] Key Accounting Data and Financial Indicators During this reporting period, the company's operating revenue increased by 30.42% year-on-year, net profit attributable to shareholders increased by 13.42%, and net profit excluding non-recurring gains and losses increased by 70.14%, with total assets and net assets attributable to shareholders also growing Key Accounting Data and Financial Indicators (Current Reporting Period vs. Same Period Last Year) | Indicator | Current Reporting Period (RMB) | Same Period Last Year (RMB) | Year-on-Year Change | | :--- | :--- | :--- | :--- | | Operating Revenue | 629,197,790.08 | 482,425,424.71 | 30.42% | | Net Profit Attributable to Shareholders of Listed Company | 128,592,907.80 | 113,380,825.19 | 13.42% | | Net Profit Attributable to Shareholders of Listed Company Excluding Non-recurring Gains and Losses | 161,776,715.50 | 95,083,548.35 | 70.14% | | Net Cash Flow from Operating Activities | 156,155,024.91 | 163,422,457.83 | -4.45% | | Basic Earnings Per Share (RMB/share) | 0.17 | 0.15 | 13.33% | | Diluted Earnings Per Share (RMB/share) | 0.17 | 0.15 | 13.33% | | Weighted Average Return on Net Assets | 1.71% | 1.53% | Increased by 0.18 percentage points | | Period-End Indicators | Current Period-End (RMB) | Previous Year-End (RMB) | Change from Previous Year-End | | Total Assets | 9,092,603,391.24 | 8,991,376,516.63 | 1.13% | | Net Assets Attributable to Shareholders of Listed Company | 7,603,913,228.64 | 7,475,317,745.70 | 1.72% | Differences in Accounting Data under Domestic and Overseas Accounting Standards During the reporting period, the company had no differences in net profit and net assets between financial reports disclosed under International Accounting Standards or overseas accounting standards and Chinese Accounting Standards - The company had no differences in net profit and net assets under domestic and overseas accounting standards during the reporting period[21][22] Non-Recurring Gains and Losses and Amounts The total non-recurring gains and losses for this reporting period amounted to RMB -33,183,807.70, primarily due to the one-time impact of estimated limestone mining rights fees, combined with government subsidies and structured deposit income Non-Recurring Gains and Losses and Amounts | Item | Amount (RMB) | Explanation | | :--- | :--- | :--- | | Gains and losses from disposal of non-current assets | 6,388.04 | | | Government subsidies included in current profit and loss | 6,650,576.04 | Mainly due to subsidiaries receiving VAT refunds for comprehensive resource utilization and government support funds | | Gains and losses from entrusted investments or asset management | 206,035.80 | Structured deposit income | | One-time impact on current profit and loss due to adjustments in tax, accounting, and other laws and regulations | -45,895,612.00 | Estimated limestone mining rights fees for the period from July 1, 2017, to December 31, 2024, already consumed | | Other non-operating income and expenses apart from the above | 72,000.40 | | | Less: Income tax impact | -5,933,928.57 | | | Impact on minority interests (after tax) | 157,124.55 | | | Total | -33,183,807.70 | | Management Discussion and Analysis Company's Main Businesses During the Reporting Period The company primarily engages in industrial investment and management and private equity fund management, with core assets including building materials manufacturing, biopharmaceutical R&D and production, and private equity fund management companies; during the reporting period, the company's building materials business faced market challenges, biopharmaceutical business benefited from GLP-1 drug market expansion, and private equity investment business developed steadily under policy support - The company's main businesses cover building materials manufacturing, biopharmaceutical R&D and production, and private equity fund management[27] - The company's strategic positioning focuses on new industrialization, artificial intelligence, and biotechnology, aligning with national scientific and technological innovation to lead a modern industrial system, targeting new technologies, models, and consumption[31] Company Introduction Sichuan Shuangma, established in 1998 and listed in 1999, primarily manages building materials, biopharmaceuticals, and private equity funds, with its building materials business in Yibin benefiting from regional infrastructure, its biopharmaceutical business centered on Shenzhen Jianyuan focusing on peptide R&D and production with global supply capabilities, and its private equity fund management business, Xizang Jinhe, managing nearly RMB 28 billion across diverse investment sectors - The company's building materials manufacturing business produces cement, commercial clinker, and aggregates, with annual capacities of 2 million tons and 5 million tons respectively, benefiting from infrastructure projects in Yibin City[28] - The company's biopharmaceutical business, centered on Shenzhen Jianyuan, specializes in peptide product R&D and production, covering peptide APIs, CDMO, and cosmetic peptides, with core APIs registered in multiple countries and global supply capabilities[29](index